

**Senate Community Affairs Committee**

**ANSWERS TO ESTIMATES QUESTIONS ON NOTICE**

**HEALTH PORTFOLIO**

**Budget Estimates 2017 - 2018, 29 & 30 May 2017**

**Ref No:** SQ17-000770

**OUTCOME:** 4 - Individual Health Benefits

**Topic:** Life Saving Drugs Program

**Type of Question:** Written Question on Notice

**Senator:** Watt, Murray

**Question:**

When can the Australian rare disease community expect to see a response on the LSDP review and what this means for the funding of new medicines? Is there a clear timeframe for when this will be announced?

**Answer:**

The response to the Life Saving Drugs Program (LSDP) review report is a matter for government. While the outcomes of the review are under consideration, the LSDP is continuing to operate under existing guidelines, including for the assessment of new listing applications. The LSDP is continuing to provide life-saving medicines for patients who require them. This includes the listing of elosulfase alfa (Vimizim®) on the LSDP for the treatment of mucopolysaccharidosis Type IV A (MPS IV A), also known as Morquio A syndrome), from 1 August 2017.